2022 Semiannual Report
DIRUI
Net profit growth of over 20% in the first half of the year
Significant Chinese market optimization
DIRUI disclosed its 2022 semi-annual report in the evening of August 11. During the reporting period, DIRUI achieved revenue of RMB 515 million, representing a year-on-year increase of 23.27%. DIRUI achieved a net profit of RMB 133 million, representing a year-on-year increase of 20.65%. DIRUI has transformed from a R&D-oriented to a sales-oriented company. Its strategic optimization has helped it grow rapidly and has gradually produced positive results.
DIRUI introduced that it would continue to focus on the primary medical market in China and proactively seize the opportunity to replace imported products. It would also use its diverse range of instruments to boost the marketing of its high-speed test products. During the reporting period, DIRUI's revenue from instrument products increased by 49.52% year-on-year. DIRUI's gynecological secretion and coagulation analysis systems, standardized laboratory, and other new pipeline products have been recognized by the market, laying a solid foundation for the subsequent increase in reagent sales.
Mr. An Guozhu, Secretary of the Board of DIRUI, said that DIRUI offers a diversified range of products. It actively supports the national policy to focus on the primary medical market and facilitate the construction of new infrastructure in the healthcare sector. DIRUI will continue to strengthen its channel construction in the Chinese market. Based on key provinces and regions, it will drive the marketing of new products through superior product lines. It will also enhance its brand influence through academic exchanges, thereby vigorously expanding its direct sales channels.
During the reporting period, more than 130 agents were added to the Chinese market. There is currently a strong market demand in county areas. Therefore, DIRUI focuses on primary healthcare through its gynecology, biochemistry and immunology lines and standardized laboratories. According to the analysis of the market feedback, there is an increase in the number of customers contracted for the DIRUI standardized laboratory. This is expected to be DIRUI's most promising production line. The standardized laboratory is DIRUI's fully self-developed PRC-made pipeline. It has modules for input, centrifugation, serum identification, de-capping, and cup dispensing. Its efficient and balanced sample detection and intelligent sample handling can enhance management efficiency.
Since the COVID-19 outbreak, large Grade III, Level A hospitals and regional central laboratories in China have been more concerned about improving the biosafety of their testing departments. DIRUI has a fully enclosed design of the standardized laboratory, which is stable, cost-effective, and can be flexibly customized to meet customer needs. DIRUI will focus on promoting this product in a market-oriented manner to support rapid corporate development.
